According to Edwards Lifesciences's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 10.4971. At the end of 2024 the company had a P/E ratio of 10.6.
Year | P/E ratio | Change |
---|---|---|
2024 | 10.6 | -67.87% |
2023 | 33.0 | 8.39% |
2022 | 30.5 | -43.11% |
2021 | 53.5 | -22.74% |
2020 | 69.3 | 49.1% |
2019 | 46.5 | 4.37% |
2018 | 44.5 | 16.54% |
2017 | 38.2 | 8.87% |
2016 | 35.1 | 1.98% |
2015 | 34.4 | 106.95% |
2014 | 16.6 | -11.75% |
2013 | 18.8 | -46.71% |
2012 | 35.4 | 3.53% |
2011 | 34.2 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() Boston Scientific BSX | 73.6 | 601.16% | ๐บ๐ธ USA |
![]() Merit Medical MMSI | 44.1 | 320.51% | ๐บ๐ธ USA |
![]() LeMaitre Vascular LMAT | 40.4 | 284.55% | ๐บ๐ธ USA |
![]() CryoLife CRY | N/A | N/A | ๐บ๐ธ USA |
![]() Medtronic MDT | 26.1 | 148.25% | ๐ฎ๐ช Ireland |
![]() ICU Medical
ICUI | -33.3 | -417.46% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.